- Home
- CNFR vs APLM Comparison
CNFR vs APLM Comparison
Compare CNFR & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- APLM
- Stock Information
- Founded
- CNFR 2009
- APLM 2016
- Country
- CNFR United States
- APLM United States
- Employees
- CNFR N/A
- APLM N/A
- Industry
- CNFR Property-Casualty Insurers
- APLM Blank Checks
- Sector
- CNFR Finance
- APLM Finance
- Exchange
- CNFR Nasdaq
- APLM Nasdaq
- Market Cap
- CNFR 13.7M
- APLM 12.3M
- IPO Year
- CNFR 2015
- APLM N/A
- Fundamental
- Price
- CNFR $1.02
- APLM $9.56
- Analyst Decision
- CNFR
- APLM Strong Buy
- Analyst Count
- CNFR 0
- APLM 2
- Target Price
- CNFR N/A
- APLM $425.00
- AVG Volume (30 Days)
- CNFR 12.2K
- APLM 36.2K
- Earning Date
- CNFR 11-13-2024
- APLM 02-15-2025
- Dividend Yield
- CNFR N/A
- APLM N/A
- EPS Growth
- CNFR N/A
- APLM N/A
- EPS
- CNFR 2.40
- APLM N/A
- Revenue
- CNFR $74,815,000.00
- APLM $2,101,000.00
- Revenue This Year
- CNFR N/A
- APLM N/A
- Revenue Next Year
- CNFR $7.00
- APLM N/A
- P/E Ratio
- CNFR $0.42
- APLM N/A
- Revenue Growth
- CNFR N/A
- APLM 70.54
- 52 Week Low
- CNFR $0.65
- APLM $6.50
- 52 Week High
- CNFR $1.91
- APLM $91.00
- Technical
- Relative Strength Index (RSI)
- CNFR 41.56
- APLM 46.48
- Support Level
- CNFR $0.98
- APLM $9.50
- Resistance Level
- CNFR $1.06
- APLM $10.67
- Average True Range (ATR)
- CNFR 0.08
- APLM 0.92
- MACD
- CNFR -0.01
- APLM -0.04
- Stochastic Oscillator
- CNFR 19.28
- APLM 13.17
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.